NCT03562494 - VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions

Parkinson's Disease

Interventions

BIOLOGICAL

VY-AADC02

Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain

OTHER

Sham (Placebo) Surgery

Bilateral partial burr/twist holes without dura penetration

Trial Locations (11)

NYU Langone Medical Center, New York

University of Pittsburgh Medical Center (UPMC), Pittsburgh

University of Philadelphia, Dept of Neurology, Philadelphia

Emory University Hospital, Atlanta

Ohio State University Clinical Trials Management Office, Columbus

Northwestern Medical Faculty Foundation, Chicago

University of Kansas Medical Center, Kansas City

University of Colorado, Aurora

UC Irvine, Irvine

University of California, San Francisco, San Francisco

UC Davis Health System, Sacramento